Inhibition of tumor cell growth by Schiff bases of hydroxysemicarbazide

Shijun Ren, Zoltan A. Tokes, Csaba Csipke, Bingsen Zhou, Yun Yen, Eric J. Lien

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The inhibitory activities of Schiff bases of hydroxysemicarbazide (HSC) against eight human and murine tumor cell lines and one non-cancer cell line were studied using MTS/PES microculture tetrazolium and methylene blue assays. Compounds 1 (1-[9-(10-methylanthryl)methylene]-4-HSC), 2 (1-[2-hydroxy-3,5-dibromobenzylidene]-4-HSC) and 3 (1-[2,3,4-trihydroxybenzylidene]-4-HSC), which have been shown to be active against murine leukemia L1210 cells in our laboratories, inhibited human leukemia CCRF-CEM cells with similar IC50s ranging from 2.7 to 7.0 μM. Of the compounds tested against attached tumor cell lines (B16, CHO, HT29, ZR75) at 50 μM concentration, compound 1 showed the strongest inhibition, followed by 4 (1-[2-(5-nitrothienyl)-methylene]-4-HSC), 2 and 5 (1-[2-hydroxy-3,5-diiodobenzylidene]-4-HSC) with more than 50% inhibition. The IC50s of compound 1 were found to range from 2.7 to 12 μM against the attached tumor cell lines examined. As compared with hydroxyurea, compound 1 had more favorable selectivity against tumor cells. Further more, compound 1 was found to have IC50s of 2.8 and 6.5 μM against hydroxyurea-resistant and gemcitabine-resistant KB cells, respectively, but had no cross-resistance with hydroxyurea and gemcitabine (two known ribonucleotide reductase inhibitors acting at different sites of the same enzyme). In conclusion, several Schiff bases of HSC showed inhibition of tumor cell growth at micromolar concentration and had no cross-resistance with hydroxyurea-resistant KB cells.

Original languageEnglish
Pages (from-to)3445-3451
Number of pages7
JournalAnticancer Research
Volume21
Issue number5
Publication statusPublished - Dec 1 2001
Externally publishedYes

Fingerprint

Hydroxyurea
Schiff Bases
gemcitabine
Tumor Cell Line
KB Cells
Growth
Neoplasms
Ribonucleotide Reductases
Leukemia L1210
Methylene Blue
Leukemia
Cell Line
Enzymes

Keywords

  • Antitumor activity
  • Cytotoxicity
  • Hydroxyurea
  • Ribonucleotide reductase
  • Schiff bases of hydroxysemicarbazide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ren, S., Tokes, Z. A., Csipke, C., Zhou, B., Yen, Y., & Lien, E. J. (2001). Inhibition of tumor cell growth by Schiff bases of hydroxysemicarbazide. Anticancer Research, 21(5), 3445-3451.

Inhibition of tumor cell growth by Schiff bases of hydroxysemicarbazide. / Ren, Shijun; Tokes, Zoltan A.; Csipke, Csaba; Zhou, Bingsen; Yen, Yun; Lien, Eric J.

In: Anticancer Research, Vol. 21, No. 5, 01.12.2001, p. 3445-3451.

Research output: Contribution to journalArticle

Ren, S, Tokes, ZA, Csipke, C, Zhou, B, Yen, Y & Lien, EJ 2001, 'Inhibition of tumor cell growth by Schiff bases of hydroxysemicarbazide', Anticancer Research, vol. 21, no. 5, pp. 3445-3451.
Ren S, Tokes ZA, Csipke C, Zhou B, Yen Y, Lien EJ. Inhibition of tumor cell growth by Schiff bases of hydroxysemicarbazide. Anticancer Research. 2001 Dec 1;21(5):3445-3451.
Ren, Shijun ; Tokes, Zoltan A. ; Csipke, Csaba ; Zhou, Bingsen ; Yen, Yun ; Lien, Eric J. / Inhibition of tumor cell growth by Schiff bases of hydroxysemicarbazide. In: Anticancer Research. 2001 ; Vol. 21, No. 5. pp. 3445-3451.
@article{a5c1e3bbfbdb478297d2b5c93ea34741,
title = "Inhibition of tumor cell growth by Schiff bases of hydroxysemicarbazide",
abstract = "The inhibitory activities of Schiff bases of hydroxysemicarbazide (HSC) against eight human and murine tumor cell lines and one non-cancer cell line were studied using MTS/PES microculture tetrazolium and methylene blue assays. Compounds 1 (1-[9-(10-methylanthryl)methylene]-4-HSC), 2 (1-[2-hydroxy-3,5-dibromobenzylidene]-4-HSC) and 3 (1-[2,3,4-trihydroxybenzylidene]-4-HSC), which have been shown to be active against murine leukemia L1210 cells in our laboratories, inhibited human leukemia CCRF-CEM cells with similar IC50s ranging from 2.7 to 7.0 μM. Of the compounds tested against attached tumor cell lines (B16, CHO, HT29, ZR75) at 50 μM concentration, compound 1 showed the strongest inhibition, followed by 4 (1-[2-(5-nitrothienyl)-methylene]-4-HSC), 2 and 5 (1-[2-hydroxy-3,5-diiodobenzylidene]-4-HSC) with more than 50{\%} inhibition. The IC50s of compound 1 were found to range from 2.7 to 12 μM against the attached tumor cell lines examined. As compared with hydroxyurea, compound 1 had more favorable selectivity against tumor cells. Further more, compound 1 was found to have IC50s of 2.8 and 6.5 μM against hydroxyurea-resistant and gemcitabine-resistant KB cells, respectively, but had no cross-resistance with hydroxyurea and gemcitabine (two known ribonucleotide reductase inhibitors acting at different sites of the same enzyme). In conclusion, several Schiff bases of HSC showed inhibition of tumor cell growth at micromolar concentration and had no cross-resistance with hydroxyurea-resistant KB cells.",
keywords = "Antitumor activity, Cytotoxicity, Hydroxyurea, Ribonucleotide reductase, Schiff bases of hydroxysemicarbazide",
author = "Shijun Ren and Tokes, {Zoltan A.} and Csaba Csipke and Bingsen Zhou and Yun Yen and Lien, {Eric J.}",
year = "2001",
month = "12",
day = "1",
language = "English",
volume = "21",
pages = "3445--3451",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Inhibition of tumor cell growth by Schiff bases of hydroxysemicarbazide

AU - Ren, Shijun

AU - Tokes, Zoltan A.

AU - Csipke, Csaba

AU - Zhou, Bingsen

AU - Yen, Yun

AU - Lien, Eric J.

PY - 2001/12/1

Y1 - 2001/12/1

N2 - The inhibitory activities of Schiff bases of hydroxysemicarbazide (HSC) against eight human and murine tumor cell lines and one non-cancer cell line were studied using MTS/PES microculture tetrazolium and methylene blue assays. Compounds 1 (1-[9-(10-methylanthryl)methylene]-4-HSC), 2 (1-[2-hydroxy-3,5-dibromobenzylidene]-4-HSC) and 3 (1-[2,3,4-trihydroxybenzylidene]-4-HSC), which have been shown to be active against murine leukemia L1210 cells in our laboratories, inhibited human leukemia CCRF-CEM cells with similar IC50s ranging from 2.7 to 7.0 μM. Of the compounds tested against attached tumor cell lines (B16, CHO, HT29, ZR75) at 50 μM concentration, compound 1 showed the strongest inhibition, followed by 4 (1-[2-(5-nitrothienyl)-methylene]-4-HSC), 2 and 5 (1-[2-hydroxy-3,5-diiodobenzylidene]-4-HSC) with more than 50% inhibition. The IC50s of compound 1 were found to range from 2.7 to 12 μM against the attached tumor cell lines examined. As compared with hydroxyurea, compound 1 had more favorable selectivity against tumor cells. Further more, compound 1 was found to have IC50s of 2.8 and 6.5 μM against hydroxyurea-resistant and gemcitabine-resistant KB cells, respectively, but had no cross-resistance with hydroxyurea and gemcitabine (two known ribonucleotide reductase inhibitors acting at different sites of the same enzyme). In conclusion, several Schiff bases of HSC showed inhibition of tumor cell growth at micromolar concentration and had no cross-resistance with hydroxyurea-resistant KB cells.

AB - The inhibitory activities of Schiff bases of hydroxysemicarbazide (HSC) against eight human and murine tumor cell lines and one non-cancer cell line were studied using MTS/PES microculture tetrazolium and methylene blue assays. Compounds 1 (1-[9-(10-methylanthryl)methylene]-4-HSC), 2 (1-[2-hydroxy-3,5-dibromobenzylidene]-4-HSC) and 3 (1-[2,3,4-trihydroxybenzylidene]-4-HSC), which have been shown to be active against murine leukemia L1210 cells in our laboratories, inhibited human leukemia CCRF-CEM cells with similar IC50s ranging from 2.7 to 7.0 μM. Of the compounds tested against attached tumor cell lines (B16, CHO, HT29, ZR75) at 50 μM concentration, compound 1 showed the strongest inhibition, followed by 4 (1-[2-(5-nitrothienyl)-methylene]-4-HSC), 2 and 5 (1-[2-hydroxy-3,5-diiodobenzylidene]-4-HSC) with more than 50% inhibition. The IC50s of compound 1 were found to range from 2.7 to 12 μM against the attached tumor cell lines examined. As compared with hydroxyurea, compound 1 had more favorable selectivity against tumor cells. Further more, compound 1 was found to have IC50s of 2.8 and 6.5 μM against hydroxyurea-resistant and gemcitabine-resistant KB cells, respectively, but had no cross-resistance with hydroxyurea and gemcitabine (two known ribonucleotide reductase inhibitors acting at different sites of the same enzyme). In conclusion, several Schiff bases of HSC showed inhibition of tumor cell growth at micromolar concentration and had no cross-resistance with hydroxyurea-resistant KB cells.

KW - Antitumor activity

KW - Cytotoxicity

KW - Hydroxyurea

KW - Ribonucleotide reductase

KW - Schiff bases of hydroxysemicarbazide

UR - http://www.scopus.com/inward/record.url?scp=0035572016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035572016&partnerID=8YFLogxK

M3 - Article

C2 - 11848507

AN - SCOPUS:0035572016

VL - 21

SP - 3445

EP - 3451

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -